长春瑞滨联合奥沙利铂二线治疗复发性卵巢癌的临床观察  

The clinical observation of vinorelbine and oxaliplatin in relapse ovarian cancer

作　　者：唐三元[1] 殷耒兰 陈琳[1] 苏菊[1] 黄卫国[2] 李跃华[1] 伍小平[1] 朱红波[1] 

机构地区：[1]南华大学附属第一医院肿瘤内科,湖南衡阳421001 [2]南华大学肿瘤研究所,湖南衡阳421001

出　　处：《中国现代医生》2013年第14期80-81,共2页China Modern Doctor

基　　金：湖南省自然科学衡阳联合基金(10JJ9017)

摘　　要：目的观察长春瑞滨联合奥沙利铂治疗复发卵巢癌的疗效及不良反应。方法本组22例患者给予长春瑞滨和奥沙利铂治疗,连用2个周期后进行影像学检查、CA125评价疗效和观察不良反应。结果完全缓解(CR)1例(4.54%),部分缓解(PR)8例(36.36%),稳定(SD)9例(40.9%),进展(PD)4例(18.2%),总有效率(CR+PR)40.9%。不良反应主要为血液系统毒性、胃肠道反应和神经系统毒性,但均未影响继续治疗,总体疗效满意。恶心呕吐17例(77.27%),神经毒性、感觉异常13例(59.09%),白细胞下降15例(68.18%);血小板下降11例(50.0%);贫血5例(22.73%),均在Ⅲ度以下。结论长春瑞滨联合奥沙利铂治疗复发性卵巢癌患者疗效确切,毒性反应可以耐受。Objective To research the effectiveness and adverse reaction of vinorelbine and oxaliplatin in relapse ovarian cancer. Methods A total of 22 patients in the group were treated with vinorelbine and oxaliplatin,after two cycle, they repeated imaging, CA125 and researched effectiveness and adverse reaction. Results The complete remission （CR） rate was 4.54% （1/22）, the patial remission rate was 36.36%（8/22）, the stable disease rate was 40.9%（9/22）, the progressive disease rate was 18.2%（4/22）,and the response rate was 40.9%（9/22）. The nausea and vomiting incidence was 17 patients（77.27%）, neurotoxicity and cacesthesia was 13 patients（59.09%）, leucocytopenia was 15 patients（68.18%）, thrombocytopenia was 11 patients（50.0%）, anemia was 5 patients （22.73%）, all below grade Ⅲ. Conclusion Vinorelbine and oxaliplatin treated relapse ovarian cancer had good effeeiacy, the tolerance was good.

关 键 词：卵巢癌 长春瑞滨 奥沙利铂 化疗 疗效 毒性反应 

分 类 号：R737.31[医药卫生—肿瘤]